Literature DB >> 31808577

Increased Liver Localization of Lipopolysaccharides in Human and Experimental NAFLD.

Guido Carpino1, Maria Del Ben2, Daniele Pastori2, Roberto Carnevale3,4, Francesco Baratta2, Diletta Overi5, Heather Francis6, Vincenzo Cardinale3, Paolo Onori5, Samira Safarikia7, Vittoria Cammisotto8, Domenico Alvaro7, Gianluca Svegliati-Baroni9, Francesco Angelico10, Eugenio Gaudio5, Francesco Violi2,4.   

Abstract

BACKGROUND AND AIMS: Lipopolysaccharides (LPS) is increased in nonalcoholic fatty liver disease (NAFLD), but its relationship with liver inflammation is not defined. APPROACH AND
RESULTS: We studied Escherichia coli LPS in patients with biopsy-proven NAFLD, 25 simple steatosis (nonalcoholic fatty liver) and 25 nonalcoholic steatohepatitis (NASH), and in mice with diet-induced NASH. NASH patients had higher serum LPS and hepatocytes LPS localization than controls, which was correlated with serum zonulin and phosphorylated nuclear factor-κB expression. Toll-like receptor 4 positive (TLR4+ ) macrophages were higher in NASH than simple steatosis or controls and correlated with serum LPS. NASH biopsies showed a higher CD61+ platelets, and most of them were TLR4+ . TLR4+ platelets correlated with serum LPS values. In mice with NASH, LPS serum levels and LPS hepatocyte localization were increased compared with control mice and associated with nuclear factor-κB activation. Mice on aspirin developed lower fibrosis and extent compared with untreated ones. Treatment with TLR4 inhibitor resulted in lower liver inflammation in mice with NASH.
CONCLUSIONS: In NAFLD, Escherichia coli LPS may increase liver damage by inducing macrophage and platelet activation through the TLR4 pathway.
© 2020 by the American Association for the Study of Liver Diseases.

Entities:  

Year:  2020        PMID: 31808577     DOI: 10.1002/hep.31056

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  61 in total

1.  Sparcl1 promotes nonalcoholic steatohepatitis progression in mice through upregulation of CCL2.

Authors:  Bin Liu; Liping Xiang; Jing Ji; Wei Liu; Ying Chen; Mingfeng Xia; Yuejun Liu; Wenyue Liu; Peiwu Zhu; Yi Jin; Yu Han; Jieli Lu; Xiaoying Li; Minghua Zheng; Yan Lu
Journal:  J Clin Invest       Date:  2021-10-15       Impact factor: 14.808

2.  Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease.

Authors:  Naoto Fujiwara; Naoto Kubota; Emilie Crouchet; Bhuvaneswari Koneru; Cesia A Marquez; Arun K Jajoriya; Gayatri Panda; Tongqi Qian; Shijia Zhu; Nicolas Goossens; Xiaochen Wang; Shuang Liang; Zhenyu Zhong; Sara Lewis; Bachir Taouli; Myron E Schwartz; Maria Isabel Fiel; Amit G Singal; Jorge A Marrero; Austin J Fobar; Neehar D Parikh; Indu Raman; Quan-Zhen Li; Masataka Taguri; Atsushi Ono; Hiroshi Aikata; Takashi Nakahara; Hayato Nakagawa; Yuki Matsushita; Ryosuke Tateishi; Kazuhiko Koike; Masahiro Kobayashi; Takaaki Higashi; Shigeki Nakagawa; Yo-Ichi Yamashita; Toru Beppu; Hideo Baba; Hiromitsu Kumada; Kazuaki Chayama; Thomas F Baumert; Yujin Hoshida
Journal:  Sci Transl Med       Date:  2022-06-22       Impact factor: 19.319

Review 3.  Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).

Authors:  Xiaohan Xu; Kyle L Poulsen; Lijuan Wu; Shan Liu; Tatsunori Miyata; Qiaoling Song; Qingda Wei; Chenyang Zhao; Chunhua Lin; Jinbo Yang
Journal:  Signal Transduct Target Ther       Date:  2022-08-13

4.  Relationship between non-invasively detected liver fibrosis and in-hospital outcomes in patients with acute coronary syndrome undergoing PCI.

Authors:  Flavio Giuseppe Biccirè; Francesco Barillà; Emanuele Sammartini; Edoardo Maria Dacierno; Gaetano Tanzilli; Daniele Pastori
Journal:  Clin Res Cardiol       Date:  2022-08-11       Impact factor: 6.138

5.  Feedback loop between hepatocyte nuclear factor 1α and endoplasmic reticulum stress mitigates liver injury by downregulating hepatocyte apoptosis.

Authors:  Si-Ying Liu; Jian-Xu Rao; Jie Deng; Gui-Juan Zhang; Xiao-Ling Jiang; Jing Cheng; Huan Chen; Zhi-Gang Jiang; De-Lin Xu; Yi-Huai He
Journal:  Sci Rep       Date:  2022-07-08       Impact factor: 4.996

Review 6.  Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC.

Authors:  Hyunmi Kim; Da Som Lee; Tae Hyeon An; Hyun-Ju Park; Won Kon Kim; Kwang-Hee Bae; Kyoung-Jin Oh
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

7.  mInd the gAP: Intestinal Alkaline Phosphatase Puts the Breaks on Atherosclerosis.

Authors:  Thomas Q de Aguiar Vallim; Elizabeth J Tarling
Journal:  Circ Res       Date:  2021-05-27       Impact factor: 23.213

8.  Hepatocyte TLR4 triggers inter-hepatocyte Jagged1/Notch signaling to determine NASH-induced fibrosis.

Authors:  Junjie Yu; Changyu Zhu; Xiaobo Wang; KyeongJin Kim; Alberto Bartolome; Paola Dongiovanni; Katherine P Yates; Luca Valenti; Michele Carrer; Thorsten Sadowski; Li Qiang; Ira Tabas; Joel E Lavine; Utpal B Pajvani
Journal:  Sci Transl Med       Date:  2021-06-23       Impact factor: 17.956

Review 9.  Gut microbiota and systemic immunity in health and disease.

Authors:  Bernard C Lo; Grace Y Chen; Gabriel Núñez; Roberta Caruso
Journal:  Int Immunol       Date:  2021-03-31       Impact factor: 4.823

Review 10.  Human Gut Microbiome and Liver Diseases: From Correlation to Causation.

Authors:  Rui Li; Zhengsheng Mao; Xujun Ye; Tao Zuo
Journal:  Microorganisms       Date:  2021-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.